Cellular signaling via receptor for advanced glycation end products (RAGE) results in pro-inflammatory responses. RAGE-mediated inflammation has been implicated in inflammatory diseases including diabetes, atherosclerosis, and Alzheimers disease. The spliced or proteolytically cleaved form of RAGE is referred to as soluble RAGE (sRAGE), which functions as a natural decoy counter-effecting RAGE signaling. It has been demonstrated in animal models that administration of sRAGE blocks atherogenesis, and stabilizes existing plaques on the vessel wall. In addition, sRAGE also prevents the formation of neointima prompted by vascular injuries and hence inhibits restenosis. We have developed Chinese Hamster Ovary (CHO) cell lines that stably express sRAGE, and the accompanying affinity purification strategies that produce homogenous sRAGE. We also generated recombinant Adenovirus that expresses sRAGE. Systemic studies of sRAGE application in restenosis animal models have been completed, and data have been analyzed. Our results showed that sRAGE produced in our laboratory exhibits 500-1000 x higher efficacy than that of sRAGE produced in insect sf9 cells. In addition to blocking restenosis, we also tested sRAGE blockage on infarct animal models and obtained promising preliminary results. We also performed studies to explore the molecular basis of the observed high potency of sRAGE and found that N-glycan structure in sRAGE contributes to its bioactivity. To further develop sRAGE as an effective therapeutic product, we used GeneOptimizer algorithm from Invitrogen to optimize T7-sRAGE----this tool removes sequence repeat, killer motifs, splice sites and RNA secondary structures in the cDNA sequence and optimize codon usage (for CHO cell) and GC content without changing protein sequence. We also tested and found that the new sRAGE cDNA has a higher level of expression than that of native cDNA. This step should enhance future sRAGE scale-up production. A patent (PCT/US2013/020103) based on sRAGE has been filed by NIH, and the OTT is currently advertising the invention. RAGE (KO) is at early stage (designing targeting vector).
|Low, Daren; Subramaniam, Renuka; Lin, Li et al. (2015) Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9. Oncotarget 6:36535-50|
|Tae, Hyun-Jin; Petrashevskaya, Natalia; Ahmet, Ismayil et al. (2014) Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model. Curr Ther Res Clin Exp 76:110-5|
|Tae, Hyun-Jin; Kim, Ji Min; Park, Sungha et al. (2013) The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth. J Mol Med (Berl) 91:1369-81|
|Pang, John; Zeng, Xiaokun; Xiao, Rui-ping et al. (2009) Design, generation, and testing of mammalian expression modules that tag membrane proteins. Protein Sci 18:1261-71|
|Lin, Li; Park, Sungha; Lakatta, Edward G (2009) RAGE signaling in inflammation and arterial aging. Front Biosci 14:1403-13|